severe allergic asthma
Respiratory · 2009–2016
5decisions
1medicine
3carried consumer input
5individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| omalizumab Treatment of severe allergic asthma in patients aged 6 to less than 12 years who have failed to achieve adequate control despite optimised asthma therapy. | Jul 2016 | Recommended with restriction | input received |
| omalizumab Amendment to PBS eligibility criteria for severe allergic asthma to extend baseline IgE threshold from ≥76 IU/mL to ≥30 IU/mL in patients treated with maximal… | Nov 2015 | Recommended with restriction | input received |
| omalizumab Treatment of patients aged 12 years or older with uncontrolled severe allergic asthma who have failed to achieve adequate control with optimised asthma therapy. | Nov 2014 | Recommended | 5 individuals |
| omalizumab initial and continuing treatment of patients with uncontrolled severe allergic asthma, who are 12 years of age or older and meet certain criteria. | Nov 2010 | Recommended | no section in document |
| omalizumab Initial and continuing treatment of patients with uncontrolled severe allergic asthma, aged 12 years or older, who have failed to achieve adequate control with… | Nov 2009 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.